Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
PubMed 22962027 TB-4 Phase 1 human safety first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin 4 in healthy volunteers, no serious adverse events: PubMed 34346165
For comprehensive healing protocols, many researchers combine GHK-CU with other peptides to address different aspects of tissue repair
GHK-Cu drives remodeling and gene-expression signaling
After about 46 half-lives, the circulating drug level becomes very low, meaning most of the parent peptide has been cleared from systemic circulation
Under the direction of Dr
US$ 28.86
US$ 25.07
US$ 23.78
